Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Raltitrexed in Advanced Colorectal Cancer
NCT03344614Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in colorectal cancer (CRC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03344614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344614.